The GID Group, Inc. provides hospitals, clinics, or medical practices with a versatile tissue processing system, capable of use with different processing methods and different tissue types. The GID SystemTM includes sterile disposable canister products for collecting and processing tissue, and associated procedures and methods to rapidly, effectively and safely process tissue. The system provides practitioners and researchers repeatable, predictable and cost effective results, and includes real-time quality assays of cell count and viability.

Our Mission

The past several years have seen rapid expansion of scientific and medical research related to the therapeutic potential of regenerative cells, especially regenerative cells from adipose tissue, yet broad adoption of cell-based therapies has not kept pace. GID intends to enable broad adoption of regenerative therapies by meeting the common need of physicians and researchers for reliable and cost-effective tissue processing to obtain the necessary cells in real time.
The GID SystemTM allows a wide range of tissue volumes to be processed in a single run, and use of a range of reagent blends and buffers; this flexibility allows the GID SystemTM to meet different tissue and volume requirements depending on therapeutic needs, and enables new therapies by giving practitioners and researchers a standardized yet modular system for tissue processing.

GID 700

The GID 700TM is a sterile single-use disposable tissue canister used for harvesting, filtering, and transferring of autologous adipose tissue. The GID 700TM is CE mark certified, and is distributed in the United States by LifeCell Corporation as the "Revolve".


The GID SVF-1TM is a sterile single-use disposable tissue canister used for harvesting, filtering, separating, concentrating, and transferring autologous tissue components for reintroduction to the same patient during a single surgical procedure for repair, reconstruction, or replacement of integumentary or musculoskeletal tissues. The GID SVF-1TM is designed for easy and fast separation and concentration of the Stromal Vascular Fraction cells from tissue for tissue repair, reconstruction, or replacement in the same surgical procedure. The GID SVF-1TM is CE mark certified, and is not available in the United States.

Quality & Cost

The GID SystemTM includes thorough quality and process control systems designed to be simple and reliable; this allows optimized processing for maximal cell yields tuned to specific requirements and a real-time assessment for the physician or researcher.

GID's disposables and components are produced in QSR, ISO 13485, MDD 93/42/EEC certified manufacturing facilities. GID proprietary reagent blends produced by certified manufacturer with GMP production capability. Because the GID SystemTM is modular and scalable, disposable and reagent costs are optimized for the required volume; the GID SystemTM also uses off-the-shelf laboratory equipment wherever possible, thus minimizing the cost associated with custom capital equipment.


Methods of separating and concentrating the Stromal Vascular Fraction (SVF) components from adipose tissue are well-known and widely published (see Literature Citations: 2,7,9,10,11). The basic form of all methods is to harvest adipose tissue in the form of lipoaspirate, use a collagenase enzyme to disaggregate and separate the tissue components, then concentrate the tissue components by density gradation using a centrifuge. Methods vary in the presence or lack of washing steps, amount and concentration of collagenase used, time of the enzyme reaction, temperature maintenance, and technique for removal of waste tissues. Methods also vary widely by type of equipment used such as sterile collection canisters, test tubes, filters, tubing sets, Falcon tubes, and other general laboratory equipment applicable to tissue processing.

Using the GID system, the entire process occurs within a single disposable container. The system provides fast, repeatable, predictable and cost effective results, and includes real-time quality assays of cell count and viability.

Literature Citations

1. Calabrese, C., et al., Breast reconstruction after nipple/areola-sparing mastectomy using cell-enhanced fat grafting. Ecancermedicalscience, 2009. 3: p. 116.

2. Cervelli, V., et al., Application of enhanced stromal vascular fraction and fat grafting mixed with PRP in post-traumatic lower extremity ulcers. Stem Cell Res, 2011. 6(2): p. 103-11.

3. Kamakura, T. and K. Ito, Autologous cell-enriched fat grafting for breast augmentation. Aesthetic Plast Surg, 2011. 35(6): p. 1022-30.

4. Levi, B. and M.T. Longaker, Concise review: adipose-derived stromal cells for skeletal regenerative medicine. Stem Cells, 2011. 29(4): p. 576-82.

5. Moseley, T.A., M. Zhu, and M.H. Hedrick, Adipose-derived stem and progenitor cells as fillers in plastic and reconstructive surgery. Plast Reconstr Surg, 2006. 118(3 Suppl): p. 121S-128S.

6. Perez-Cano, R., et al., Prospective trial of adipose-derived regenerative cell (ADRC)-enriched fat grafting for partial mastectomy defects: the RESTORE-2 trial. Eur J Surg Oncol, 2012. 38(5): p. 382-9.

7. Rodriguez, J.P., et al., Autologous stromal vascular fraction therapy for rheumatoid arthritis: rationale and clinical safety. Int Arch Med, 2012. 5: p. 5.

8. Yoshimura, K., et al., Cell-assisted lipotransfer for cosmetic breast augmentation: supportive use of adipose-derived stem/stromal cells. Aesthetic Plast Surg, 2008. 32(1): p. 48-55; discussion 56-7.

9. Yoshimura, K., et al., Cell-assisted lipotransfer for facial lipoatrophy: efficacy of clinical use of adipose-derived stem cells. Dermatol Surg, 2008. 34(9): p. 1178-85.

10. Astori, G., et al., "In vitro" and multicolor phenotypic characterization of cell subpopulations identified in fresh human adipose tissue stromal vascular fraction and in the derived mesenchymal stem cells. J Transl Med, 2007. 5: p. 55.

11. Yoshimura, K., et al., Characterization of freshly isolated and cultured cells derived from the fatty and fluid portions of liposuction aspirates. J Cell Physiol, 2006. 208(1): p. 64-76

The GID Group, Inc. is a consortium of world-leading plastic surgeons, adipose tissue scientists, and seasoned entrepreneurial managers that use a deep science-based approach to create a reliable, cost-effective tissue processing platform that enables a broad range of therapies based on regenerative cells derived from human tissue.

Founders and Management


William Futrell M.D. Founder


Adam Katz M.D.



Ramon Llull M.D. Ph.D. Founder


G. Patrick Maxwell M.D. Founder


William Cimino Ph.D.



Frank DiLazzaro

Sr VP Global Bus Dev


Dale Tomrdle

Sr VP Opns & Finance

J.William Futrell, M.D. received his MD from Duke University, followed by General Surgery Residency at Case-Western Reserve University and Plastic Surgery Residency at Johns Hopkins University. He was a Clinical/Research Oncology Fellow in the Surgery Branch at the National Institutes of Health and is Board Certified in General Surgery and in Plastic and Reconstructive Surgery. He was Professor and Chief of Plastic Surgery at the University of Pittsburgh Medical Center for 21 years, is Past President of the American Association of Plastic Surgeons and multiple other medical organizations and author or co-author of more than 200 peer-reviewed scientific publications. As an entrepreneur he is co-inventor of multiple patents and co-founder of numerous businesses including CellSource, Inc.; StemSource, Inc.; Human Analytix, Inc.; Illumineer, Inc.; and Life Science Enhancement Corporation. He is currently Chairman and co-founder of The GID Group, Inc.

Lou Bucky, M.D.


Dan Delvecchio, M.D.


Jeffrey I. Kurland, M.D.,Ph.D.


Ramon Llull, M.D.,Ph.D.

SAB Lou Bucky bio

Board of Directors



St. John


Adam Katz M.D.


William Futrell M.D. Chairman


Ruben Diaz


Jesse Shefferman


William Cimino, Ph.D.

Morgan St. John is the Managing Partner of Wyvern Capital and has been active in merchant banking and investment banking since 1978. He has originated, analyzed, structured, negotiated and syndicated approximately $40 billion of corporate transactions in the U.S., Europe, Asia and Latin America. Mr. St. John has successfully assisted and collaborated with numerous investment groups including Manhattan Pacific Partners, Actian Capital, Boyer Capital, Washington Partners, Wilson Partners, and Morpheus Capital. Prior to Wyvern Capital, Mr. St. John was a Partner and Managing Director at Banker Trust Company where he built the Los Angeles Finance group and New York Syndication group to become the industry leaders in highly structured acquisition financing. Mr. St. John has both his Bachelors and Masters degrees from Harvard University.
International Headquarters

The GID Group, Inc.

901 Front St. Suite 240

Louisville, CO USA 80027

For general information please click on the link below to send us an email: